Immune checkpoint inhibitors (ICI), such as anti-PD-1 and anti-CTLA-4, have shown promise in several types of cancer, but there is no obvious clinical benefit for GBM patients, largely due to the cold nature of TME3. This evidence concerns the gene CTLA4 and glioblastoma.